This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek ® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. Details of the poster presentations are listed below.


Radiological Society of North America Conference (RSNA)


November 25-30, 2012



Poster Title 1:

In Phase 3 Clinical Studies in Melanoma and Breast Cancer, Receptor-Targeted (CD206) Tc 99m Tilmanocept Provided Enhanced Intraoperative Lymphatic Mapping, Leading to Increased Pathology Findings in Patients and Upstaging in Pathology-Positive Patient


Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Sessions, Monday, Nov. 26, 2012, 12:15 – 12:45 p.m.

Poster Title 2:

A Phase 3 Clinical Trial Employing Tc 99m Tilmanocept, a Novel CD206-Targeted Intraoperative Lymphatic Mapping Agent For Breast Cancer and Melanoma, Shows Significant Concordance between Preoperative Imaging and Intraoperative Localization of Disease


Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Sessions, Wednesday, Nov. 28, 2012, 12:45 – 1:15 p.m.


CTRC-AACR San Antonio Breast Cancer Symposium


December 4-8, 2012


San Antonio, Texas

Poster Title:

Tc 99m Tilmanocept and Sulfur Colloid Injection: A comparison of Preoperative Imaging and Intraoperative Lymphatic Mapping of Breast Cancer Patients – Localization Rate and Degree of Localization


Frederick Cope, Ph.D., Navidea Biopharmaceuticals

Session, Date:

Poster Session 1, Wednesday, Dec. 5, 2012, 5 – 7 p.m.

About Lymphoseek ®

Lymphoseek ® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs